Theriva Biologics Inc (TOVX)

[Ann1]

What do you mean they missed the primary endpoint?!

"After 24 months of treatment, the reduction in relapse rate persisted in favor of the Trimesta plus Copaxone treatment group compared to the Copaxone plus placebo group (32 percent). Both treatment groups exhibited improvement in measures of cognitive function at 24 months. Treatment was safe and well tolerated with no evidence of adverse effects on breast or uterus."

Improvement at 12 AND 24 months -- 47 vs. 32% (12 versus 24) makes sense because Copaxone generally takes about a year to start working.

Let the losers spin away. These results are GREAT. I am sure there will be intested in Trimesta out there, for both patients and potential buyers.

Congratulations to longs! This is a success.